Skip to main content
SpringerLink
Log in

Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation

  • Original Article
  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

The effects of a bombesin/gastrin releasing peptide (BB/GRP) receptor antagonist, PD176252, and histone deacetylase (HDAC) inhibitor, MS-275, were investigated on human lung cancer cell lines. Using the MTT assay, PD176252 and MS-275 inhibited the proliferation of NCI-H1299 cells with IC50 values of 7 and 5 μg/mL, respectively. Using MS-275 and PD176252 together, the ability to inhibit lung cancer cellular growth increased significantly. The combination index for MS-275 and PD176252 was < 0.2, indicating that the compounds are highly synergistic in inhibiting lung cancer cellular growth. Also, MS-275 and PD 176252 together strongly inhibited the clonal growth of NCI-H345 or NCI-H1299 cells. MS-275 had little effect on the expression of lung cancer cellular GRP or GRP receptors, but increased expression of transforming growth factor-β receptor II (TGF-β RII). These results indicate that GRP receptor antagonists may potentiate the action of histone deacetylase inhibitors on lung cancer cellular proliferation by increasing expression of tumor suppressor genes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ashwood V., Brownhill V., Higgenbottom M., et al. (1998) PD176252-the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. J Bioorg. Med. Chem. Lett. 8, 2589–2594.

    Article  CAS  Google Scholar 

  • Carney D. N., Cuttitta F., Moody T. W., and Minna J. D. (1987) Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin releasing peptide. Cancer Res. 47, 821–825.

    PubMed  CAS  Google Scholar 

  • Chang T. H., and Szabo E. (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferators-activated receptor-gamma and inhibitors of histone deacety lase inadenocarcinoma of the lung. Clin Cancer Res. 8, 1206–1212.

    PubMed  CAS  Google Scholar 

  • Choi Y. H. (2005) Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int. J. Oncol. 27, 473–479.

    PubMed  CAS  Google Scholar 

  • Chou T. C., and Talalay P (1983) Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol. Sci. 4, 450–454.

    Article  CAS  Google Scholar 

  • Corjay M. H., Dobrzanski J, Way J. M., et al. (1991) Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J. Biol. Chem. 266, 18,771–18,779.

    CAS  Google Scholar 

  • Cuttitta F., Carney D. N., Mulshine J., et al. (1985) Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316, 823–825.

    Article  PubMed  CAS  Google Scholar 

  • Denlinger C. E., Keller M. D., Mayo M. W., Broad R. M., and Jones D. R. (2004) Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 127, 1078–1086.

    Article  PubMed  CAS  Google Scholar 

  • Draoui M., Chung P., Park M, Birrer M, Jakowlew S., and Moody T. W. (1995) Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cells. Peptides 16, 289–292.

    Article  PubMed  CAS  Google Scholar 

  • Jakowlew, S. B., Moody T. W., Mariano J. M. (1997) Transforming growth factor β receptors in human cancer cell lines: analysis of transcript, protein and proliferation. Anticancer Res., 17, 1849–1860.

    PubMed  CAS  Google Scholar 

  • Jones P. A., and Baylin S. B. (2002) The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3, 415–428.

    Article  PubMed  CAS  Google Scholar 

  • Koh S. W. M., Leyton J., and Moody T. W. (1999) Bombesin activates MAP kinase in non-small cell lung cancer cells. Peptides 20, 121–126.

    Article  PubMed  CAS  Google Scholar 

  • Korman L. Y., Carney D. N., Citron M. L., and Moody T. W. (1986) Secretin/VIP stimulated secretion of bombesin-like peptides from human small cell lung cancer. Cancer Res. 46, 1214–1218.

    PubMed  CAS  Google Scholar 

  • Mahmoud S., Staley J., Taylor, J., et al. (1991) (Psi13,14) Bombesin analogues inhibit the growth of small cell lung cancer in vitro and in vivo. Cancer Res. 51, 1798–1802.

    PubMed  CAS  Google Scholar 

  • Massague J. (1998) TGF-beta signal transduction. Ann. Rev. Biochem. 67, 753–791.

    Article  PubMed  CAS  Google Scholar 

  • Massague J. and Wotton D. (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19, 1745–1754.

    Article  PubMed  CAS  Google Scholar 

  • Maxhimer J. B., Reddy R. M., Zuo J., Cole G. W., Schrump D. S., and Nguyen D. M. (2005) Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C). J. Thorac. Cardiovasc. Surg. 129, 53–63.

    Article  PubMed  CAS  Google Scholar 

  • Mayo M. W., Denlinger C. E., Broad R. M., et al. (2003) Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J. Biol. Chem. 278, 18,089–18,096.

    Google Scholar 

  • Moody T. W., Carney D. N., Cuttitta F., Quattrochi K., and Minna J. D. (1985) High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci. 37, 105–113.

    Article  PubMed  CAS  Google Scholar 

  • Moody T. W., Leyton J., Garcia L., and Jensen R. T. (2003) Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur. J. Pharmacol. 474, 21–29.

    Article  PubMed  CAS  Google Scholar 

  • Moody T. W., Mantey S. A., Pradhan T., et al. (2004) Development of high affinity camptothecin-bombesin conjugates which have targeted cytotoxicity for bombesin receptor-containing cells. J. Biol. Chem. 279, 23,580–23,589.

    Article  CAS  Google Scholar 

  • Moody T. W., Murphy A., Mahmoud S., and Fiskum G. (1987) Bombesin-like peptides elevate cytosolic calcium in small cell lung cancer cells. Biochem. Biophys. Res. Commun. 147, 189–195.

    Article  PubMed  CAS  Google Scholar 

  • Moody T. W., Pert C. B., Gazdar A. F., Carney D. N., and Minna J. D. (1981) High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 214, 1246–1248.

    Article  PubMed  CAS  Google Scholar 

  • Moody T. W., Zia F., Venugopal R., Patierno S., LeBan J., and McDermod J. (1995). BW 2258: A GRP receptor antagonist which inhibits small cell lung cancer growth. Life Sci. 56, 523–529.

    Article  Google Scholar 

  • Oster S. K., Ho C. S., Soucie E. L., and Penn I. Z. (2002) The myc oncogene: marvelously complex. Adv. Cancer Res. 84, 81–154.

    Article  PubMed  CAS  Google Scholar 

  • Rachwal W. J., Bongiorno P. F., Orringer M. D., Whyte R. I., Ethier S. P., and Beer D. G. (1995) Expression and activation of erb B-2 and epidermal growth factor receptor in lung adenocarcinomas. Br. J. Cancer 72, 56–64.

    PubMed  CAS  Google Scholar 

  • Reissmann P. T., Koga H., Takahashi R., et al. (1993) Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 8, 1913–1919.

    PubMed  CAS  Google Scholar 

  • Reid T., Valone F., Lipera W., et al. (2004) Phase II trial of histone deacetylase inhibitor pivaloyloxymethyly butyrate (Pivanex) in advanced non-small cell lung cancer. Lung Cancer 45, 381–386.

    Article  PubMed  Google Scholar 

  • Richon W. M., Sandhoff T. W., Rifkind R. A., and Marks P. A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97, 10,014–10,019.

    Article  CAS  Google Scholar 

  • Saito A., Yamashita T., Mariko Y., et al. (1999) A synthetic inhibitor of histone deacetylase, Ms-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96, 4592–4597.

    Article  PubMed  CAS  Google Scholar 

  • Scatchard G. J. (1949) The attractions of proteins for small molecules and ions. Ann. NY Acad. Sci. 51, 660–679.

    Article  CAS  Google Scholar 

  • Sonnemann J., Gangel J., Kumar K. S., Muller C., Bader P., Beck, J. F. (2005) Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cells. Invest. New Drugs. 23, 99–109.

    Article  PubMed  CAS  Google Scholar 

  • Taylor, J. E., Moreau J. P., Baptiste, L., Moody, T. W. (1991). Octapeptide analogues of somatostatin inhibit the clonal growth and vasoactive intestinal peptide stimulated cyclic AMP formation in human small cell lung cancer cells. Peptides 12, 839–844.

    Article  PubMed  CAS  Google Scholar 

  • Ten Dijke P., Miyazono K., and Heldin C. H. (2000) Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends. Biochem. Sci. 25, 64–70.

    Article  PubMed  Google Scholar 

  • Toyooka S., Tsuda T., Gazdar A. F. (2003) The TP53 gene, tobacco exposure and lung cancer. Hum. Mutat. 21, 229–239.

    Article  PubMed  CAS  Google Scholar 

  • Whitman M. (1997) Signal transduction. Feedback from inhibitory SMADs. Nature 389, 549–551.

    Article  PubMed  CAS  Google Scholar 

  • Whitmarsh A. J., and Davies R. J. (1996) Transcription factor AP-1 regulation by mitogen activated protein kinase signal transduction pathways. J. Mol. Med. 17, 589–607.

    Article  Google Scholar 

  • Yoo J., Ghiassi M., Jirmanova L., et al. (2003) Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J. Biol. Chem. 278, 43,001–43,007.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health and Human Services, Office of the Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD

    Terry W. Moody

  2. Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD

    Tomoo Nakagawa & Robert T. Jensen

  3. Cell and Cancer Biology Branch, National Cancer Institute, Rockville, MD

    Yang Kang & Sonia Jakowlew

  4. University of Colorado Health Science Center, Denver, CO

    Daniel Chan

Authors
  1. Terry W. Moody
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoo Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sonia Jakowlew
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniel Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert T. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terry W. Moody.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moody, T.W., Nakagawa, T., Kang, Y. et al. Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J Mol Neurosci 28, 231–238 (2006). https://doi.org/10.1385/JMN:28:3:231

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/JMN:28:3:231

Index Entries

Search

Navigation